PTGX - Quick Take - JNJ 2Q call indicates continued strong launch for ICOTYDE, PsA data in 2H, IBD trial execution

Research evidence excerpt

PTGX - Quick Take - JNJ 2Q call indicates continued strong launch for ICOTYDE, PsA data in 2H, IBD trial execution

Truist Securities

(including Truist Bank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Truist Bank

may have a lending relationship with companies mentioned herein. Certain clients may compensate Truist Securities, Inc. for research

via hard dollar payments, and Truist Securities, Inc. may be deemed to be an investment adviser to such clients as a result of such

payments.

Please see our Disclosure Database to search by ticker or company name for the current required disclosures, including valuation and

risks. Link: https://truist.bluematrix.com/sellside/Disclosures.action

Please visit the Truist Securities Equity Research Portal for coverage universe, current reports, and analyst roster with contact

information. Link: https://truist-portal.bluematrix.com

Truist Securities, Inc., member FINRA and SIPC. Truist, Truist Bank, Truist Securities, Truist Investment Services, and Truist Advisory

Services are service marks of Truist Financial Corporation.

If you no longer wish to receive this type of communication, please request removal by sending an email to

EquityResearchDepartment@truist.com

© Truist Securities, Inc. 2026. All rights reserved. Reproduction or quotation in whole or part without permission is forbidden. Without

Truist Securities’ prior written consent, the contents of this report may not be used, in whole or in part, in connection with the training,

development, fine-tuning or operation of a machine learning or artificial intelligence system, tool or application.

ADDITIONAL INFORMATION IS AVAILABLE at our website, TruistSecurities.com, or by writing to: Truist Securities, Research